Both are possible but I also believe there are several factors. First you have the consistent trading down by traders manipulating the price and presentation of misinformation. Easy to do on low volume. The stock is heavily undervalued and this is obvious to all. So working the price down increases the money you make and decreases any risk but the MMs here are not your normal retail MMs.
I have also thought about the run to .97 and the shorting that likely occurred and the covering that ensues....What ran it .97? Only one person claims P&D and when asked for where the pump was, there is no answer. Even an article was written that claimed a pump but everyone that investigated it, found nothing.
Lots of money on the side that will buy the stock at .60 before they buy it at .20.
Price is the only thing that can be manipulated and logic would conflate price to company success but that would be false logic in the short term.
My opinion is lack of retail support based on low earnings and high OS. When we see good earnings even with R&D you will see the retail support. When NH said grow "organically" what did you think that meant? true sustainable growth is based on earnings.
Same game since I started buying in the .06's. Has a single thing changed in terms of moving the PPS down since 2011 or spreading misinformation about the company? Answer- not a thing. The stock was and is highly undervalued- was known back in 2012 and it is known now and the removal of Elite's going concern from their SEC filings proves it. Look at the daily wash trading between retail on Level 2 with 2500 trades being the most common- walk the PPS down on low volume- pick up cheap shares- let the PPS rise 5-7% - confine to sell and wash trade shares after the rise- and buy back cheaper making small amounts of money until the inevitable happens- ART is launched and then non retail MM's will tell the small retails it's no longer their game to play.
It will happen- it happens with every successful stock that has technology that gives Big Pharma a run for their money. And Elite has technology better than Purdue and Pfizer and we all know it. The two bead modular tech proves it- but by the time the company proves it on the market- that's the time Elite will get bought out. But hey Elite doesn't even have to have better tech - which it does- it just has to get it to market.
But I've already answered this question a dozen times- and every time I do- flippers are looking for a run. We have a run in the making- just a matter of how long before that NDA filing???
Two other things nobody seems to ever answer-
1) who was doing all the buying on the run to .97 (25 million volume)?
2) nobody can tell me one single thing wrong with Elite's tech. And in the end, that will dwarf any efforts to squash the PPS.
News 
Market Data 
Discover 
